Physician profile
Wayne A Breer
NPI 1255324703
$12,680.02
in general payments reported to CMS, 2019-2025
40 companies · $2,256 in 2025
The $2,256 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $1,190 · 2021: $1,447 · 2022: $1,807 · 2023: $1,834 · 2024: $2,027 · 2025: $2,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,729 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,728.69 |
| Education | $387.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,988.00 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $1,219.36 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $851.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $586.58 | 2019-2025 | |
| Ucb, INC. | $578.25 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $572.54 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $541.51 | 2023-2024 | Vtama |
| Amgen INC. | $534.64 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $452.18 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $450.39 | 2021-2025 | Opzelura |
| Prugen, INC. Pharmaceuticals | $417.88 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $340.26 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $276.32 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $273.72 | 2019-2025 | |
| Almirall LLC | $263.57 | 2019-2025 | Klisyri, Seysara |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Breer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.